Channel Therapeutics Corporation
CHROAMEXHealthcare
$1.35
+$0.09(+7.14%)
Market Cap$8904398
P/E Ratio—
52W High$54.29
52W Low$1.2301
Channel Therapeutics Corporation (CHRO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CHRO · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Mar 19, 2026EPS Actual
-$1.15
Revenue
$0.01B
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Mar 19, 2026
After Market Close
CHRO reports quarterly as a AMEX-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q1 FY2026 | Mar 19, 2026 | — | -$1.15 | — | $0.01B | — | — |
| — Q4 FY2025 | Nov 13, 2025 | — | -$5.30 | — | $0.01B | — | — |
| — Q3 FY2025 | Aug 12, 2025 | — | -$0.31 | — | — | — | — |
| — Q2 FY2025 | May 13, 2025 | — | -$0.32 | — | — | — | — |
| ▼ Q1 FY2025 | Mar 27, 2025 | -$0.21 | -$0.32 | -52.4% | $0.00B | — | — |
| ▼ Q4 FY2024 | Nov 13, 2024 | -$0.23 | -$0.29 | -26.1% | — | — | — |
| — Q3 FY2024 | Aug 13, 2024 | -$0.31 | -$0.31 | +0.0% | — | — | — |
| — Q2 FY2024 | May 15, 2024 | — | -$0.55 | — | — | — | — |
Q1 FY2026
Mar 19, 2026
EPS Actual
-$1.15
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Q4 FY2025
Nov 13, 2025
EPS Actual
-$5.30
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Q3 FY2025
Aug 12, 2025
EPS Actual
-$0.31
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 13, 2025
EPS Actual
-$0.32
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Mar 27, 2025Miss
EPS Actual
-$0.32
EPS Est.
-$0.21
EPS Surpr.
-52.4%
Revenue
$0.00B
Q4 FY2024
Nov 13, 2024Miss
EPS Actual
-$0.29
EPS Est.
-$0.23
EPS Surpr.
-26.1%
Revenue
—
Q3 FY2024
Aug 13, 2024
EPS Actual
-$0.31
EPS Est.
-$0.31
EPS Surpr.
+0.0%
Revenue
—
Q2 FY2024
May 15, 2024
EPS Actual
-$0.55
EPS Est.
—
EPS Surpr.
—
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $-0.25 | $-0.25 | $-0.25 | 1 |
| Q3 FY2025 | $-0.26 | $-0.26 | $-0.26 | 1 |
| Q2 FY2025 | $-0.31 | $-0.31 | $-0.31 | 1 |
| Q1 FY2025 | $-0.29 | $-0.29 | $-0.29 | 1 |
| Q4 FY2024 | $-0.21 | $-0.21 | $-0.21 | 1 |
| Q3 FY2024 | $-0.23 | $-0.23 | $-0.23 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q1 FY2026 | Mar 19, 2026 | — | $22.14 | — | — |
| — Q4 FY2025 | Nov 13, 2025 | — | $22.14 | — | — |
| — Q3 FY2025 | Aug 12, 2025 | — | $22.14 | — | — |
| — Q2 FY2025 | May 13, 2025 | — | $10.80 | $10.70 | -0.93% |
| ▼ Q1 FY2025 | Mar 27, 2025 | -52.4% | $14.50 | $14.80 | +2.07% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -26.1% | $6.36 | $6.41 | +0.79% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +0.0% | $7.34 | $7.65 | +4.22% |
| — Q2 FY2024 | May 15, 2024 | — | $21.70 | $21.10 | -2.76% |
Q1 FY2026—
Report Date
Mar 19, 2026
EPS Beat/Miss
—
Price Before
$22.14
Price After
—
Q4 FY2025—
Report Date
Nov 13, 2025
EPS Beat/Miss
—
Price Before
$22.14
Price After
—
Q3 FY2025—
Report Date
Aug 12, 2025
EPS Beat/Miss
—
Price Before
$22.14
Price After
—
Q2 FY2025-0.93%
Report Date
May 13, 2025
EPS Beat/Miss
—
Price Before
$10.80
Price After
$10.70
Q1 FY2025+2.07%
Report Date
Mar 27, 2025
EPS Beat/Miss
-52.4%
Price Before
$14.50
Price After
$14.80
Q4 FY2024+0.79%
Report Date
Nov 13, 2024
EPS Beat/Miss
-26.1%
Price Before
$6.36
Price After
$6.41
Q3 FY2024+4.22%
Report Date
Aug 13, 2024
EPS Beat/Miss
+0.0%
Price Before
$7.34
Price After
$7.65
Q2 FY2024-2.76%
Report Date
May 15, 2024
EPS Beat/Miss
—
Price Before
$21.70
Price After
$21.10
Avg Beat Reaction+4.22%
Avg Miss Reaction+1.43%
Beat Rate1 / 8 quarters
Largest Move+4.22% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CHRO ends December
Channel Therapeutics Corporation (CHRO) most recently reported earnings on March 19, 2026 for Q1 FY2026, posting EPS of $-1.15 (in line with the analyst consensus of —). The next CHRO earnings date is expected around September 1, 2026.
Each quarter, investors track CHRO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CHRO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CHRO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CHRO earnings · 4 questionsChannel Therapeutics Corporation's next earnings report is expected around September 1, 2026. CHRO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CHRO historically reports after market close (AMC).
CHRO earnings datewhen is CHRO earningsCHRO next earnings datewhen does CHRO report earningsCHRO earnings calendar
▸ Source: FMP · Channel Therapeutics Corporation SEC filings · US GAAP · Channel Therapeutics Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026